Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BOTS INC APPOINTS IT-INDUSTRY LEADER Dr. OLEKSANDR GORDIEIEV AS NEW CEO
Bots, Inc.April 12, 2021 GMT
SAN JUAN, Puerto Rico, April 12, 2021 (GLOBE NEWSWIRE) BOTS, Inc. (OTC: BTZI), a vertical integrator and an emerging innovator of products, technologies, and services for the rapidly growing digital robotics automation, cybersecurity, and manufacturing industry, announced today that its Board of directors had appointed 20-year technology industry executive Dr. Oleksandr Gordieiev as its new chief executive officer, effective May 1, 2021. He will succeed Paul Rosenberg, who will remain CEO until April 30th, 2021.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medigus: Polyrizon Commenced a Pre-Clinical Study Testing Several Formulations of its Bio-Gel .
Medigus LtdApril 12, 2021 GMT
OMER, Israel, April 12, 2021 (GLOBE NEWSWIRE) Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that Polyrizon Ltd. (which Medigus owns 33.24% of its share capital), a private company engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, commenced a pre-clinical trial to examine its bio-gel efficacy to protect against coronavirus infection.
Press release content from Newswire. The AP news staff was not involved in its creation.
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
April 12, 2021 GMT
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
SIENA, Italy - April 12, 2021 - ( Newswire.com )
Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce a publication describing the construction of a DNA-encoded chemical library (DEL) that was successfully screened against multiple protein targets, yielding potent and selective small molecule binders against disease-relevant antigens.
Press release content from Newswire. The AP news staff was not involved in its creation.
Philogen Announces Participation to the 10th World Congress of Melanoma
April 12, 2021 GMT
Philogen Announces Participation to the 10th World Congress of Melanoma
SIENA, Italy - April 12, 2021 - ( Newswire.com )
Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce its participation in the 10th World Congress of Melanoma, a virtual event taking place from April 15 to 17, 2021.
Philogen, which is one of the sponsors of this congress, will give a poster presentation with the title: “A phase II study of intralesional Daromun (L19IL2 + L19TNF) in non-melanoma skin cancer patients with localized disease (NCT04362722)”. The poster will be on display for registered participants starting from Monday, April 12, 2021.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Avantor® to Acquire Ritter GmbH and its Affiliates; Expands Proprietary Offering for Diagnostic and Drug Discovery Workflows
April 12, 2021 GMT
Avantor introduces new brand identity (PRNewsfoto/Avantor)
RADNOR, Pa. and SCHWABMÜNCHEN, Germany, April 12, 2021 /PRNewswire/ Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, announced today that it has entered into a definitive agreement to acquire privately held Ritter GmbH and its affiliates in an all-cash transaction with an upfront equity purchase price of approximately €890 million subject to final adjustments at closing and additional payments based on achieving future business performance milestones.